Ann: PTX-100 trial advances following successful Phase 1b, page-273

Hey, Deno, what you may find a particularly interesting read is the following:

Prescient Therapeutics Acquires Exclusive Worldwide Licence for Cancer Biomarker p27 - Wholesale Investor

Be sure to download and read the PDF. Its fascinating stuff particularly given that we don't know what types of solid turmors make up the 5 cohorts in our trial. And, given that we know Prof Miles Prince had at least 2 of his own patients here in Aust that responded really well in the trial. I'm certainly not going to be throwing my conjectural thoughts out there for fear of casting aspersions.

I happened to read an article today too in my Google feed relating to small biotech companies having a habit of not releasing all the detailed data of clinical results. In the case of our recent results and what is stated by Steven in the preso, I think all bodes well here!